| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2171999 | Cytotherapy | 2011 | 11 Pages |
Abstract
CTL that target at least two antigens each of CMV, EBV and Ad should have clinical benefit with broad coverage of all three viruses and enhanced control of CMV infections compared with current protocols.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Patrick J. Hanley, Donald R. Shaffer, Conrad R.Y. Cruz, Stephanie Ku, Benjamin Tzou, Hao Liu, Gail Demmler-Harrison, Helen E. Heslop, Clio M. Rooney, Stephen Gottschalk, Catherine M. Bollard,